|
WO1995003009A1
(en)
|
1993-07-22 |
1995-02-02 |
Oculex Pharmaceuticals, Inc. |
Method of treatment of macular degeneration
|
|
WO1995003807A1
(en)
|
1993-07-27 |
1995-02-09 |
The University Of Sydney |
Treatment of age-related macular degeneration
|
|
US5801195A
(en)
*
|
1994-12-30 |
1998-09-01 |
Celgene Corporation |
Immunotherapeutic aryl amides
|
|
IT1274549B
(it)
|
1995-05-23 |
1997-07-17 |
Indena Spa |
Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
|
|
US5800819A
(en)
|
1996-01-25 |
1998-09-01 |
National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology |
Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
NZ333903A
(en)
|
1996-07-24 |
2000-02-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
HN1998000115A
(es)
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
|
US6015803A
(en)
|
1998-05-04 |
2000-01-18 |
Wirostko; Emil |
Antibiotic treatment of age-related macular degeneration
|
|
US6225348B1
(en)
|
1998-08-20 |
2001-05-01 |
Alfred W. Paulsen |
Method of treating macular degeneration with a prostaglandin derivative
|
|
US6001368A
(en)
|
1998-09-03 |
1999-12-14 |
Protein Technologies International, Inc. |
Method for inhibiting or reducing the risk of macular degeneration
|
|
US6667316B1
(en)
*
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
CN1511420A
(zh)
|
2001-11-09 |
2004-07-07 |
���µ�����ҵ��ʽ���� |
运动图像编码方法和装置
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US20100129363A1
(en)
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US20050203142A1
(en)
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US20040091455A1
(en)
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US20050100529A1
(en)
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
KR20120039065A
(ko)
|
2003-12-02 |
2012-04-24 |
셀진 코포레이션 |
혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물
|
|
US20050143344A1
(en)
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
BRPI0509019A
(pt)
|
2004-03-22 |
2007-08-07 |
Celgene Corp |
métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
|
|
US20050222209A1
(en)
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
US20050239842A1
(en)
|
2004-04-23 |
2005-10-27 |
Zeldis Jerome B |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
|
US9504658B2
(en)
*
|
2004-11-09 |
2016-11-29 |
Board Of Regents, The University Of Texas System |
Stabilized HME composition with small drug particles
|
|
CN101098694A
(zh)
|
2004-11-12 |
2008-01-02 |
细胞基因公司 |
使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物
|
|
JP2008520731A
(ja)
|
2004-11-23 |
2008-06-19 |
セルジーン・コーポレーション |
中枢神経系傷害を治療及び管理するための、免疫調節性化合物を使用した方法及び組成物
|
|
SI1928492T1
(sl)
|
2005-09-01 |
2011-09-30 |
Celgene Corp |
Imunoloĺ ka uporaba imunomodulatornih spojin za cepivo in protiinfekcijsko bolezensko terapijo
|
|
CN101702878B
(zh)
*
|
2007-05-11 |
2012-11-28 |
弗·哈夫曼-拉罗切有限公司 |
可溶性差的药物的药物组合物
|
|
JP4989733B2
(ja)
*
|
2008-02-13 |
2012-08-01 |
大日本住友製薬株式会社 |
口腔内崩壊錠
|
|
MX2010010334A
(es)
*
|
2008-03-24 |
2010-10-08 |
Celgene Corp |
Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
|
|
EP2334287A4
(en)
|
2008-08-20 |
2013-12-25 |
Univ Texas |
MELT EXTRUSION OF MULTIPARTICLES WITH MODIFIED RELEASE
|
|
HRP20130356T1
(en)
|
2008-09-10 |
2013-05-31 |
Celgene Corporation |
Processes for the preparation of aminosulfone compounds
|
|
PE20120580A1
(es)
|
2009-02-10 |
2012-05-23 |
Celgene Corp |
Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
|
|
MX337893B
(es)
*
|
2009-11-10 |
2016-03-28 |
Celgene Corp |
Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion.
|
|
BR112012012999A2
(pt)
|
2009-11-30 |
2019-04-02 |
Aptalis Pharmatech, Inc. |
Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt)
|
|
WO2012096859A2
(en)
|
2011-01-10 |
2012-07-19 |
Celgene Corporation |
Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
|
|
WO2013040120A1
(en)
|
2011-09-14 |
2013-03-21 |
Celgene Corporation |
Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
|
|
RS60415B1
(sr)
|
2011-12-27 |
2020-07-31 |
Amgen (Europe) GmbH |
Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
|